Patient recruitment and enrolment solution Trialbee has entered a collaboration with Massive Bio to leverage its Omnichannel Network to boost access and participant recruitment in clinical trials in the oncology and haematology fields.

This alliance aims to connect cancer patients and their oncologists or haematologists more efficiently to trials.

The companies recognise the low participation rate in cancer clinical research, with only 6.3% of patients involved, as the US Commission on Cancer reported.

Addressing this issue is imperative to increase awareness and access to research opportunities as a viable care option.

Trialbee and Massive Bio are committed to improving patient recruitment for cancer trials, emphasising patient-focused research and complete transparency.

This approach ensures clinical sites receive the necessary information to follow up with potential study candidates effectively.

The partnership will utilise the Trialbee Honey Platform to track and handle interested patients.

This system unifies and standardises recruitment and enrolment information from all sources, offering transparency into the recruitment process and reducing the burden on clinical sites.

In December 2022, Trialbee and Acclinate partnered to increase the equitable participation of patients in trials.

Trialbee CEO Matt Walz said: “We have built our Omnichannel Network to expand the reach of our own data-driving recruitment methods without sacrificing our core principles of being highly targeted in our outreach.

“Massive Bio is a perfect example of a valuable partnership that will open new pathways for patients while still remaining hyper-focused on the ideal participant personae for each clinical trial.

“We are impressed by the team at Massive Bio, and we are proud to collaborate with them to raise awareness of clinical trial opportunities for more, and more diverse, patients and families worldwide.”